BiotechTube

N-803 and BCG + N-803

Phase 2/3Active
0 watching 0 views this week📈 Rising
62
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bladder Cancer

Conditions

Bladder Cancer

Trial Timeline

Jun 2, 2017 → Mar 1, 2029

NCT ID
NCT03022825

About N-803 and BCG + N-803

N-803 and BCG + N-803 is a phase 2/3 stage product being developed by ImmunityBio for Bladder Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT03022825. Target conditions include Bladder Cancer.

Hype Score Breakdown

Clinical
22
Activity
15
Company
7
Novelty
7
Community
8

Clinical Trials (1)

NCT IDPhaseStatus
NCT03022825Phase 2/3Active

Competing Products

20 competing products in Bladder Cancer

See all competitors
ProductCompanyStageHype Score
pegylated liposomal doxorubicin (PLD) + PD-1CSPC Pharmaceutical Group LimitedPhase 2
51
EG-70 (phase 1) + EG-70 (phase 2)enGenePhase 1/2
33
mirabegron + solifenacinAstellas PharmaApproved
85
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Enfortumab vedotinAstellas PharmaPhase 1
33
Mirabegron + PlaceboAstellas PharmaApproved
85
SolifenacinAstellas PharmaApproved
85
Mirabegron + Tolterodine + Placebo to Mirabegron + Placebo to TolterodineAstellas PharmaPhase 3
77
solifenacin succinateAstellas PharmaPhase 3
77
SolifenacinAstellas PharmaPre-clinical
23
BetanisAstellas PharmaPre-clinical
23
SolifenacinAstellas PharmaApproved
85
SolifenacinAstellas PharmaPhase 2
52
Mirabegron + Tolterodine ERAstellas PharmaApproved
85
mirabegron + solifenacin + darifenacin + imidafenacin + tolterodine + oxybutynin + trospium + fesoterodine + propiverineAstellas PharmaPre-clinical
23
Enfortumab vedotin + PembrolizumabAstellas PharmaPhase 2
52
MK-3475 + ASG-22CEAstellas PharmaPhase 2
52
Enfortumab Vedotin + PembrolizumabAstellas PharmaPhase 2
52
Alpha blocker + placebo + solifenacinAstellas PharmaApproved
85
warfarin + YM178Astellas PharmaPhase 1
33

Other Products from ImmunityBio

NAI + Pembrolizumab + NAI + Nivolumab + Ipilimumab + Pembrolizumab + NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel (Investigator's choice) + Cisplatin/carboplatin and pemetrexed plus pembrolizumab. + Cisplatin/carboplatin and pemetrexed plus atezolizumab. + Carboplatin and paclitaxel plus atezolizumab and bevacizumab. + Carboplatin and nab-paclitaxel plus atezolizumab. + NAI + Nivolumab + Ipilimumab + Carboplatin + Nab-paclitaxelPhase 3
74
N-803 + Tislelizumab + DocetaxelPhase 3
74
Aldoxorubicin + Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)Phase 3
74
hAd5-S-Fusion+N-ETSD + Placebo (0.9% (w/v) saline)Phase 2/3
62
Nab-paclitaxel + Cisplatin + 5Fluorouracil + Cyclophosphamide + ETBX-011 + ETBX-051 + ETBX-061 + GI-4000 + GI-6301 + Aldoxorubicin + Avelumab + ALT-803 + haNK + Docetaxel + carboplatinPhase 2
49